Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Trial to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+Dipeptidyl Peptidase-4-inhibitor(DPP-4-i) to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
Age
19 - No limit years
Sex
ALL
Healthy Volunteers
No
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, Seocho District, South Korea
Start Date
June 11, 2025
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
September 15, 2025
204
ESTIMATED participants
Metformin
DRUG
Dapagliflozin/Pioglitazone
DRUG
Dapagliflozin/Sitagliptin
DRUG
Lead Sponsor
Boryung Pharmaceutical Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587